XIIlab씨이랩
189330 · KOSDAQ · ₩189330 · 씨이랩
₩9,030▲ ₩360 (4.15%)End-of-day · Oct 27, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩10B | ₩9.1B | ₩3.7B | ₩9.9B | ₩5.8B |
| Cost of sales | ₩7.8B | ₩7.8B | ₩3.5B | ₩9.4B | ₩4.4B |
| Gross profit | ₩2.4B | ₩1.3B | ₩188M | ₩473M | ₩1.4B |
| Operating income | −₩3.2B | −₩5.3B | −₩6.9B | −₩4.9B | −₩2B |
| Net income | −₩3.1B | −₩5.2B | −₩6.5B | −₩4.5B | −₩2.1B |
| Net income to shareholders | −₩3.1B | −₩5.2B | −₩6.5B | −₩4.5B | −₩2.1B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩29B | ₩13B | ₩18B | ₩29B | ₩31B |
| Current assets | ₩28B | ₩10B | ₩14B | ₩24B | ₩26B |
| Cash and equivalents | ₩8.1B | ₩3.2B | ₩3.2B | ₩19B | ₩8.1B |
| Total liabilities | ₩4.3B | ₩3.8B | ₩3.2B | ₩8.1B | ₩6.8B |
| Current liabilities | ₩3.3B | ₩2.6B | ₩1.4B | ₩5.9B | ₩3.8B |
| Total equity | ₩25B | ₩9.6B | ₩15B | ₩21B | ₩25B |
| Shareholders' equity | ₩25B | ₩9.6B | ₩15B | ₩21B | ₩25B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | −₩712M | −₩3.6B | −₩5.2B | −₩4.9B | ₩848M |
| Capital spending | ₩655M | ₩576M | ₩87M | ₩384M | ₩377M |
| Free cash flow | −₩1.4B | −₩4.2B | −₩5.3B | −₩5.3B | ₩471M |
Consolidated where available. Amounts in won.
Also known as: XIIlab / 씨이랩 / 189330 / KRX:189330
Source: KRX statistical information